Michael J. Lauer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Michael J. Lauer has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Graham F. Hatfull
Department of Biological Sciences, University of Pittsburgh
4 shared publications Madison Cristinziano
Department of Biological Sciences, University of Pittsburgh , Pittsburgh, Pennsylvania
3 shared publications- Andrew P. VanDemark
Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA 15260, USA
2 shared publications Deborah Jacobs-Sera
Department of Biological Sciences, University of Pittsburgh , Pittsburgh, Pennsylvania
2 shared publications- Krista G. Freeman
Department of Biological Sciences, University of Pittsburgh, Pittsburgh, USA
2 shared publications Lawrence Abad
Department of Biological Sciences, University of Pittsburgh , Pittsburgh, Pennsylvania
2 shared publications
Latest Publications
- Open Access
Mycobacteriophage Adephagia gp48 inhibits essential host cell wall biosynthesis enzyme mannose-1-phosphate guanylyltransferase
It is common for bacteriophages to encode proteins that are strongly inhibitory to growth of the bacterial host, and about 10% of mycobacteriophage-encoded proteins have this property. Adephagia is a Cluster K1 mycobacteriophage and prior cloning and expression of 66 Adephagia non-structural genes identified 14 that are toxic when expressed in Mycobacterium smegmatis . One of the expressed proteins, the 70-residue gp48, is highly toxic when expressed in both M. smegmatis and Mycobacterium abscessus and acts by binding to and inactivating the function of Msmeg_1828, a mannose-1-phosphate guanylyltransferase (Mpg). Mpg is an essential enzyme for biosynthesis of GDP-mannose, a precursor of several key cell wall constituents including lipoarabinomannan and phosphatidylinositol mannosides. The crystal structure of Adephagia gp48 shows that the N-terminal 43 residues form two alpha helices that strongly promote dimer formation; the C-terminal 27 residues are disordered but are predicted to bind Fe-S clusters via cysteine and histidine residues. Adephagia gp48 inhibits Mpg guanylyltransferase activity in vitro and is predicted to interrupt Mpg dimer formation. The C-terminal metal binding activity of gp48 is not required for toxicity, and non-toxic mutants have substitutions in the N-terminal alpha helices that are involved in dimerization. The selective advantage of Mpg inactivation for the phage is unclear, but it may protect from competing phages that require GDP-mannose derived molecules for efficient infection. IMPORTANCE: A majority of bacteriophage-encoded proteins are of unknown function. An effective strategy for gaining functional insights into these is to identify those that are toxic when expressed in the bacterial host and determine the basis of the toxicity. We show that gp48 encoded by mycobacteriophage Adephagia is toxic when overexpressed in Mycobacterium smegmatis and Mycobacterium abscessus and the toxicity results from gp48 interaction with the host mannose-1-phosphate guanylyltransferase (Mpg) enzyme. Mpg is required for biosynthesis of GDP-Mannose, a precursor for many essential mannose-containing cellular constituents, and gp48 acts a dimer to binding to Mgp and inactivate its enzymatic activity.
Open AccessMycobacteriophage Adephagia gp48 inhibits essential host cell wall biosynthesis enzyme mannose-1-phosphate guanylyltransferase
It is common for bacteriophages to encode proteins that are strongly inhibitory to growth of the bacterial host, and about 10% of mycobacteriophage-encoded proteins have this property. Adephagia is a Cluster K1 mycobacteriophage and prior cloning and expression of 66 Adephagia non-structural genes identified 14 that are toxic when expressed in Mycobacterium smegmatis . One of the expressed proteins, the 70-residue gp48, is highly toxic when expressed in both M. smegmatis and Mycobacterium abscessus and acts by binding to and inactivating the function of Msmeg_1828, a mannose-1-phosphate guanylyltransferase (Mpg). Mpg is an essential enzyme for biosynthesis of GDP-mannose, a precursor of several key cell wall constituents including lipoarabinomannan and phosphatidylinositol mannosides. The crystal structure of Adephagia gp48 shows that the N-terminal 43 residues form two alpha helices that strongly promote dimer formation; the C-terminal 27 residues are disordered but are predicted to bind Fe-S clusters via cysteine and histidine residues. Adephagia gp48 inhibits Mpg guanylyltransferase activity in vitro and is predicted to interrupt Mpg dimer formation. The C-terminal metal binding activity of gp48 is not required for toxicity, and non-toxic mutants have substitutions in the N-terminal alpha helices that are involved in dimerization. The selective advantage of Mpg inactivation for the phage is unclear, but it may protect from competing phages that require GDP-mannose derived molecules for efficient infection. IMPORTANCE: A majority of bacteriophage-encoded proteins are of unknown function. An effective strategy for gaining functional insights into these is to identify those that are toxic when expressed in the bacterial host and determine the basis of the toxicity. We show that gp48 encoded by mycobacteriophage Adephagia is toxic when overexpressed in Mycobacterium smegmatis and Mycobacterium abscessus and the toxicity results from gp48 interaction with the host mannose-1-phosphate guanylyltransferase (Mpg) enzyme. Mpg is required for biosynthesis of GDP-Mannose, a precursor for many essential mannose-containing cellular constituents, and gp48 acts a dimer to binding to Mgp and inactivate its enzymatic activity.
- Open Access
- 15 July 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (5) , e1027-e1031
Bacteriophage Therapy of Mycobacterium abscessus Mastoiditis
We describe a case of a child with macrolide-resistant Mycobacterium abscessus who initially had clinical improvement on a dual β-lactam regimen but continued to have positive cultures. Suitable phages active against the bacterial strain were identified, administered both systemically and directly to the ear, and were associated with microbiological remission.
- 15 July 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (5) , e1027-e1031
Open AccessBacteriophage Therapy of Mycobacterium abscessus Mastoiditis
We describe a case of a child with macrolide-resistant Mycobacterium abscessus who initially had clinical improvement on a dual β-lactam regimen but continued to have positive cultures. Suitable phages active against the bacterial strain were identified, administered both systemically and directly to the ear, and were associated with microbiological remission.
- Open Access
- 12 April 2025
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (4) , 684-690
Trial design of bacteriophage therapy for nontuberculous mycobacteria pulmonary disease in cystic fibrosis: The POSTSTAMP study
- 12 April 2025
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (4) , 684-690
Open AccessTrial design of bacteriophage therapy for nontuberculous mycobacteria pulmonary disease in cystic fibrosis: The POSTSTAMP study
- Open Access
- 28 November 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-14
Use of epigenetically modified bacteriophage and dual beta-lactams to treat a Mycobacterium abscessus sternal wound infection
Nontuberculous mycobacterium (NTM) infections are challenging to manage and are frequently non-responsive to aggressive but poorly-tolerated antibiotic therapies. Immunosuppressed lung transplant patients are susceptible to NTM infections and poor patient outcomes are common. Bacteriophages present an alternative treatment option and are associated with favorable clinical outcomes. Similarly, dual beta-lactam combinations show promise in vitro, but clinical use is sparse. We report here a patient with an uncontrolled Mycobacterium abscessus infection following a bilateral lung transplant and failed antibiotic therapy. Both smooth and rough colony morphotype strains were initially present, but treatment with two phages that kill the rough strain – including epigenetic-modification to overcome restriction – resulted in isolation of only the smooth strain. The rough and smooth strains have similar antibiotic susceptibilities suggesting that the phages specifically eliminated the rough strain. Dual beta-lactam therapy with meropenem and ceftazidime-avibactam provided further clinical improvement, and the phages act synergistically with meropenem in vitro.
- 28 November 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-14
Open AccessUse of epigenetically modified bacteriophage and dual beta-lactams to treat a Mycobacterium abscessus sternal wound infection
Nontuberculous mycobacterium (NTM) infections are challenging to manage and are frequently non-responsive to aggressive but poorly-tolerated antibiotic therapies. Immunosuppressed lung transplant patients are susceptible to NTM infections and poor patient outcomes are common. Bacteriophages present an alternative treatment option and are associated with favorable clinical outcomes. Similarly, dual beta-lactam combinations show promise in vitro, but clinical use is sparse. We report here a patient with an uncontrolled Mycobacterium abscessus infection following a bilateral lung transplant and failed antibiotic therapy. Both smooth and rough colony morphotype strains were initially present, but treatment with two phages that kill the rough strain – including epigenetic-modification to overcome restriction – resulted in isolation of only the smooth strain. The rough and smooth strains have similar antibiotic susceptibilities suggesting that the phages specifically eliminated the rough strain. Dual beta-lactam therapy with meropenem and ceftazidime-avibactam provided further clinical improvement, and the phages act synergistically with meropenem in vitro.
- Open Access
- 20 July 2024
- Published by Oxford University Press (OUP) in G3: Genes, Genomes, Genetics
- Vol. 14 (9)
Characterization of mycobacteriophage Adephagia cytotoxic proteins
Mycobacterium phage Adephagia is a Cluster K phage that infects Mycobacterium smegmatis and some strains of Mycobacterium pathogens. Adephagia has a siphoviral virion morphology and is temperate. Its genome is 59,646 bp long and codes for one tRNA gene and 94 predicted protein-coding genes; most genes not associated with virion structure and assembly are functionally ill-defined. Here, we determined the Adephagia gene expression patterns in lytic and lysogenic growth and used structural predictions to assign additional gene functions. We characterized 66 non-structural genes for their toxic phenotypes when expressed in M. smegmatis, and we show that 25 of these (38%) are either toxic or strongly inhibit growth, resulting in either reduced viability or small colony sizes. Some of these genes are predicted to be involved in DNA metabolism or regulation, but others are of unknown function. We also characterize the HicAB-like toxin-antitoxin system encoded by Adephagia (gp91 and gp90, respectively) and show that the gp90 antitoxin is lysogenically expressed, abrogates gp91 toxicity, and is required for normal lytic and lysogenic growth.
- 20 July 2024
- Published by Oxford University Press (OUP) in G3: Genes, Genomes, Genetics
- Vol. 14 (9)
Open AccessCharacterization of mycobacteriophage Adephagia cytotoxic proteins
Mycobacterium phage Adephagia is a Cluster K phage that infects Mycobacterium smegmatis and some strains of Mycobacterium pathogens. Adephagia has a siphoviral virion morphology and is temperate. Its genome is 59,646 bp long and codes for one tRNA gene and 94 predicted protein-coding genes; most genes not associated with virion structure and assembly are functionally ill-defined. Here, we determined the Adephagia gene expression patterns in lytic and lysogenic growth and used structural predictions to assign additional gene functions. We characterized 66 non-structural genes for their toxic phenotypes when expressed in M. smegmatis, and we show that 25 of these (38%) are either toxic or strongly inhibit growth, resulting in either reduced viability or small colony sizes. Some of these genes are predicted to be involved in DNA metabolism or regulation, but others are of unknown function. We also characterize the HicAB-like toxin-antitoxin system encoded by Adephagia (gp91 and gp90, respectively) and show that the gp90 antitoxin is lysogenically expressed, abrogates gp91 toxicity, and is required for normal lytic and lysogenic growth.